Core Viewpoint - Luoxin Pharmaceutical Group Co., Ltd. has shown significant growth in its core product, Tegoprazan (brand name: Taixinzan®), with a nearly 140% year-on-year increase in sales in the first half of 2025, supported by favorable medical insurance policies and improved profitability [1][3][4]. Group 1: Investor Activity - The investor relations activity was conducted from December 28 to 29, 2025, involving both online and offline formats, with participation from major investment institutions [2]. - The company’s board secretary, Jiang Ying, addressed key investor concerns regarding product progress, financial performance, and research and development [2]. Group 2: Product Performance - Tegoprazan, classified as a first-class innovative drug and a P-CAB (potassium-competitive acid blocker), has made significant market advancements, with nearly 2,500 hospitals adopting the product in the first half of 2025 [3]. - The product's sales volume increased by nearly 140% compared to the previous year, and it has been included in the national medical insurance directory for three major indications, which will further enhance market penetration [3]. Group 3: Financial Performance - The company reported a gross margin of 51.8% for the first three quarters of 2025, an increase of 9 percentage points year-on-year, and a positive operating cash flow of 280 million yuan [4]. - The improvement in financial metrics is attributed to the scaling up of Tegoprazan sales and effective management of operating capital [4]. Group 4: Research and Development - The company’s R&D team focuses on unmet clinical needs in the digestive system and implements a differentiated strategy for generic drugs, ensuring supply and cost control for selected products [5]. - A plan to raise up to 842.4 million yuan through a private placement of A-shares has been approved, aimed at funding innovative drug development and expanding production capacity [5]. Group 5: Overall Outlook - Overall, Luoxin Pharmaceutical is positioned for growth driven by its innovative drug, with ongoing improvements in product structure and financial indicators, supported by research investments and refinancing efforts [7].